Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
PRINCETON, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s New Drug …